SL-START (NCT07145190) is an ongoing real-world evidence (RWE) observational study designed to evaluate titration patterns, treatment persistence, and patient outcomes with sublingual apomorphine (SL-APO) in Parkinson's disease patients experiencing motor fluctuations (OFF episodes)[1]. This study is sponsored by Bial - Portela C S.A., the pharmaceutical company that developed apomorphine sublingual formulations.
Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting approximately 10 million people globally. The cornerstone of PD treatment is dopaminergic therapy, primarily levodopa. However, with disease progression and long-term levodopa use, most patients develop motor complications:
These motor fluctuations significantly impact quality of life, activities of daily living, and overall functioning.
Apomorphine is a potent dopamine receptor agonist that provides rapid symptom relief when administered sublingually. Unlike continuous infusion therapies that require pumps and subcutaneous catheters, sublingual apomorphine offers on-demand rescue from OFF episodes with rapid onset[2].
Key Features of Sublingual Apomorphine:
While pivotal clinical trials have demonstrated the efficacy and safety of sublingual apomorphine, there is a critical gap in understanding how the therapy performs in routine clinical practice:
The SL-START study addresses these knowledge gaps through systematic collection of real-world data.
Inclusion Criteria:
Exclusion Criteria:
Baseline Visit:
Follow-up Visits (3, 6, 9, 12 months):
Primary Endpoints:
Secondary Endpoints:
As of the latest update, SL-START is actively recruiting at sites across:
The study has enrolled approximately 280 patients to date, with recruitment expected to complete by Q2 2026.
The titration of sublingual apomorphine requires careful individualization. In clinical trials, standardized titration protocols are used, but routine practice may vary significantly. SL-START will document:
This information will help establish optimal titration algorithms and identify factors influencing dose requirements.
Long-term continuation of sublingual apomorphine is critical for maintaining benefit. SL-START will identify:
SL-START provides an opportunity to compare sublingual apomorphine with:
Sublingual apomorphine works through direct activation of dopamine D1 and D2 receptors in the striatum and basal ganglia[2:1]. Unlike levodopa, which requires enzymatic conversion to dopamine, apomorphine provides immediate dopaminergic stimulation.
Pharmacodynamic Effects:
Sublingual Apomorphine Film:
Dosing Schedule:
Pivotal Trials:
The efficacy of sublingual apomorphine was established in the pivotal phase 3 program including:
Key Findings[2:2]:
Real-World Effectiveness[3]:
Common Adverse Events:
Serious Adverse Events:
Contraindications:
Sublingual vs Subcutaneous Apomorphine[4]:
| Feature | Sublingual | Subcutaneous |
|---|---|---|
| Onset | 15-30 min | 5-10 min |
| Duration | 60-90 min | 60-120 min |
| Peak effect | 30-45 min | 20-30 min |
| Nausea | Higher | Lower |
| Site reactions | None | Common |
| Convenience | High | Moderate |
Clinical Role:
| Treatment | Company | Route | Onset | Duration |
|---|---|---|---|---|
| Apomorphine SL | Bial | Sublingual | 15-30 min | 60-90 min |
| Apomorphine SC | Various | Subcutaneous | 5-10 min | 60-120 min |
| Levodopa inhalation | Acorda | Inhaled | 10 min | 30-60 min |
| Rotigotine patch | UCB | Transdermal | 2-4 hours | 24 hours |
Bial, a Portuguese pharmaceutical company, has positioned apomorphine sublingual as a flagship product:
SL-START may be extended to:
Real-world evidence from SL-START may:
SL-START represents an important initiative to understand the real-world use and outcomes of sublingual apomorphine in Parkinson's disease. By systematically collecting data on titration practices, treatment persistence, and clinical effectiveness, this study will inform optimal use of this important rescue therapy. The findings will help clinicians and patients make evidence-based decisions about sublingual apomorphine treatment, ultimately improving outcomes for people with Parkinson's disease experiencing motor fluctuations.
SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment. 2024. ↩︎
Trenkwalder C, et al. Efficacy and safety of apomorphine sublingual film for Parkinson's disease off episodes. Lancet Neurology. 2021. ↩︎ ↩︎ ↩︎
Spitzer M, et al. Sublingual apomorphine for off episodes in Parkinson's disease: clinical effectiveness in routine care. Journal of Neural Transmission. 2023. ↩︎
Katz M, et al. Apomorphine subcutaneous infusion versus sublingual tablets: a comparative analysis. Parkinsonism and Related Disorders. 2022. ↩︎